Table 3 Adverse events associated with IPF treatments
% of patients | |||
|---|---|---|---|
Grade 1–2 | Grade 3 | Grade 4 | |
N-Acetylcysteine | |||
Epigastric pain | 5 % | 0 % | 0 % |
Digestive intolerance | 8 % | 0 % | 0 % |
Dyspepsia | 5 % | 0 % | 0 % |
Reflux | 1 % | 0 % | 0 % |
Nausea | 1 % | 0 % | 0 % |
Anticoagulants | |||
Haematoma | 10 % | 0 % | 0 % |
Systemic corticosteroids | |||
Osteoporosis | 30 % | 18 % | 5 % |
Opportunistic infections | 10 % | 5 % | 1 % |
Oedema | 10 % | 3 % | 0 % |
Myopathy | 15 % | 5 % | 5 % |
Hyperglycaemia | 30 % | 18 % | 5 % |
Cushing syndrome | 20 % | 10 % | 5 % |
Compression fractures | 10 % | 10 % | 3 % |
Diabetes | 15 % | 10 % | 5 % |
Hypertension | 10 % | 5 % | 0 % |
Cataracts | 8 % | 5 % | 1 % |
Digestive intolerance | 10 % | 7 % | 3 % |
Pirfenidone | |||
Photosensitivity | 20 % | 0 % | 0 % |
Epigastric pain | 15 % | 3 % | 0 % |
Skin reactions | 15 % | 0 % | 0 % |
Nausea | 8 % | 10 % | 0 % |
Asthenia | 10 % | 3 % | 0 % |
Digestive intolerance | 10 % | 8 % | 0 % |
Long-term oxygen therapy | |||
Nasal dryness | 40 % | 10 % | 3 % |
Epistaxis | 10 % | 0 % | 0 % |
Dry mouth | 8 % | 3 % | 0 % |